Can-Fite BioPharma (CANF)

• Market cap: $7.22M
• 1 day: -1.61%
• 5 days: -13.76%
• 1 month: -31.75%
• 3 months: -36.92%
• 6 months: -61.23%
• Year to date: -76.39%
• 1 year: -80.34%
• 5 years: -97.5%
• 10 years: -99.92%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Employees: 5